SAVA 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Cassava Sciences (SAVA) Investors with $250K+ Losses to Contact Firm’s Attorneys Now, Oct. 26th Deadline in Securities Class Action
Retrieved on:
Sunday, October 24, 2021
The petition raised serious concerns about the quality and integrity of the laboratory-based studies surrounding this drug candidate.
Key Points:
- The petition raised serious concerns about the quality and integrity of the laboratory-based studies surrounding this drug candidate.
- The petition further identified errors and anomalies in the data of a sufficient frequency and magnitude to strongly suggest scientific misconduct.
- Were focused on investors losses and proving Cassava manipulated clinical data for simufilam, said Reed Kathrein, the Hagens Berman partner leading the investigation.
- Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.